Kahla, A., Saad, N., Mahmoud, I. (2018). Effectiveness of Alizapride for Prophylaxis of Nausea and Vomiting after Spinal Anesthesia for Cesarean Section. The Egyptian Journal of Hospital Medicine, 73(5), 6633-6640. doi: 10.21608/ejhm.2018.15603
Ayman Hussein Fahmy Kahla; Nasr Abdel-Aziz Mohammad Saad; Islam Mahmoud Mohamed Mahmoud. "Effectiveness of Alizapride for Prophylaxis of Nausea and Vomiting after Spinal Anesthesia for Cesarean Section". The Egyptian Journal of Hospital Medicine, 73, 5, 2018, 6633-6640. doi: 10.21608/ejhm.2018.15603
Kahla, A., Saad, N., Mahmoud, I. (2018). 'Effectiveness of Alizapride for Prophylaxis of Nausea and Vomiting after Spinal Anesthesia for Cesarean Section', The Egyptian Journal of Hospital Medicine, 73(5), pp. 6633-6640. doi: 10.21608/ejhm.2018.15603
Kahla, A., Saad, N., Mahmoud, I. Effectiveness of Alizapride for Prophylaxis of Nausea and Vomiting after Spinal Anesthesia for Cesarean Section. The Egyptian Journal of Hospital Medicine, 2018; 73(5): 6633-6640. doi: 10.21608/ejhm.2018.15603
Effectiveness of Alizapride for Prophylaxis of Nausea and Vomiting after Spinal Anesthesia for Cesarean Section
Department of Anesthesia & Intensive Care, Faculty of Medicine, Al-Azhar University
Abstract
Background: Nausea and vomiting are common side effects in parturients undergoing cesarean delivery performed under spinal anesthesia can be very unpleasant to the patients. The reported incidence of nausea and vomiting during cesarean performed under regional anesthesia varies from 50% to 80% when no prophylactic antiemetic is given. Therefore, use of prophylactic antiemetics in parturients undergoing cesarean delivery is recommended by some authors. Objective: In this study, alizapride was evaluated, as a D2 receptor antagonist, on the prevention of nausea and vomiting following Spinal Anesthesiain parturients undergoing elective cesarean section. Patients and Methods: The study was carried out in AL-Azhar University Hospitals, Obstetric and gynaecology department on 90 patients undergoing an elective, lower segment cesarean section (LSCS). All patients were identified by code number to maintain the privacy of the patients. Any unexpected risks appeared during the course of the research was cleared to the participants and the ethical committee on time. A written informed consent was obtained from all patients. Patients were divided into 3 groups, 30 patients for each group. Group I (Alizapride 50 group): Received intravenous (IV) Alizapride 50 mg diluted in 10 ml of normal saline over 1-5 minutes, immediately after clamping umbilical cord. Group II (Alizapride 100 group): Received intravenous (IV) Alizapride 100 mg diluted in 10 ml of normal saline over 1-5 minutes, immediately after clamping umbilical cord. Group III (Saline group): Received normal saline 10 ml, immediately after clamping umbilical cord. Results: The incidence of nausea and vomiting was significantly decreased in group 2 (Alizapride100 group) compared with group 1 (Alizapride 50 group) and both group was better than group 3 (control group). The use of ondansetron and chlorpheniramine was significantly decreased in group 1 and 2 when compared with group 3. Conclusion: This study concluded that Alizapride 100 mg, given intravenously immediately after clamping umbilical cord would reduce PONV and pruritus in parturients undergoing an elective cesarean section under spinal anesthesia.
View on SCiNiTO
Top